Four hundred and thirty pregnant women were recruited during their second trimester of pregnancy (M=20 weeks). They were designated depressed (N=172) or nondepressed (N=258) on the Structured Clinical Interview of Depression (SCID) and the Center for Epidemiological Studies Depression scale (CES-D). They were given a second assessment when they were approximately 32 weeks gestational age. At both assessments they were given self-report measures (CES-D, the State Anxiety Inventory, and the State Anger Inventory) and provided urine samples for assays of cortisol, catecholamines (norepinephrine, epinephrine and dopamine) and serotonin. They were also given the VITAS scale for lower back pain and leg pain and a sleep disturbance scale. The stability of mood states and biochemistry across pregnancy (20 and 32 weeks) were assessed inasmuch as mood states, and biochemistry have been noted to predict prematurity and low birthweight. Significant correlations were noted for all variables except serotonin. Relationships between mood states and biochemistry were also noted but only between cortisol and depression, cortisol and anxiety, and epinephrine and anxiety. Significant stability was noted between the 20-week measures and the 32-week measures including depression, anxiety, anger, and cortisol. These were, in turn, correlated with each other and with, low back pain, leg pain, and sleep disturbance. These data suggest the stability of mood states and cortisol across pregnancy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.infbeh.2005.12.009 | DOI Listing |
Clin Pediatr (Phila)
January 2025
Department of Pediatrics, Nanjing Lishui People's Hospital, Nanjing, China.
Background: Compassion fatigue is a state of emotional and physical exhaustion that arises from frequent contact with people who have experienced trauma or stress, which may affect particularly those working in health care. This study aimed to elucidate the prevalence and determinants of compassion fatigue among pediatric nurses.
Methods: A survey was administered to pediatric nurses at a tertiary hospital in Jiangsu province, China.
Alzheimers Dement
December 2024
Acumen Pharmaceuticals, Charlottesville, VA, USA.
Background: Incorporation of the patient voice into drug development has been recognized as fundamental; recent legislation has addressed the importance of collecting patient experience data. Qualitative patient interviews conducted in tandem with clinical trials, often in later phases, are among the most common means of eliciting these data. To assess aspects of patient experience earlier in development, we conducted semi-structured qualitative interviews following participation in the phase 1 ACU-001 (INTERCEPT-AD) trial, a study evaluating the safety and tolerability of the Aβ oligomer-targeting monoclonal antibody ACU193, among a subset of participants with mild cognitive impairment (MCI) or mild Alzheimer's disease (AD) and their study partners.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of Michigan, Ann Arbor, MI, USA.
Background: Examination of family caregiving and the stress process has focused on a "primary" caregiver (e.g., spouse, adult child) at the exclusion of other members of the caregiving network.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
IDEAS Institute, Cleveland Heights, OH, USA.
Background: Neurobehavioral distress significantly impacts people with dementia. Lighting interventions have shown positive effects in this population, yet most did not accommodate natural daylight. This study developed an innovative, bright light system, the smart ambient bright light (SABL), that provides auto-controlled, consistent indoor lighting and accommodates natural daylight.
View Article and Find Full Text PDFBackground: With the recent approval of disease modifying therapies (DMT) for early Alzheimer's disease, there is a need for prescribing physicians to accurately communicate expectations of treatment effects to patients and their care partners. To better understand potential challenges and solutions to enhance this communication, physicians were surveyed, after which patients and care partners participated in focus groups.
Method: Step one consisted of an online survey of 100 US-based neurologists, geriatric medicine specialists and Alzheimer's disease specialists to ascertain physician perspectives on meaningful benefits associated with anti-amyloid monoclonal antibody treatment (DMT) over currently available symptomatic treatments.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!